The potential reassessment of cannabinoids, particularly at the federal level, is generating considerable anticipation within the market. A shift away from Schedule I status, often considered as outdated and hindering innovation, could unlock significant possibilities for companies. Reduced regulatory restrictions, alongside greater access to banki